Skin Ulcers - Pipeline Review, H2 2012

Skin Ulcers – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Skin Ulcers - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin Ulcers.
- A review of the Skin Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Skin Ulcers Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Skin Ulcers 7
Skin Ulcers Therapeutics under Development by Companies 9
Skin Ulcers Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Skin Ulcers Therapeutics – Products under Development by Companies 13
Skin Ulcers Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Skin Ulcers Therapeutics Development 15
Galderma S.A. 15
Skin Ulcers – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
HO/03/03 - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
oxandrolone - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Thymosin beta-4 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GK567 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Skin Ulcers Therapeutics – Discontinued Products 26
Skin Ulcers Therapeutics - Dormant Products 27
Skin Ulcers – Product Development Milestones 28
Featured News & Press Releases 28
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment 28
Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results 28
Sep 24, 2008: HealOr Announces $15 Million Investment Led By Mori Arkin To Heal Chronic Wounds 29
Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137 30
Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial 31
Apr 26, 2008: HealOr’s Leading Drug HO/03/03 Receives Recognition From The Wound Healing Society In The SAWC&WHS 2008 Conference In San Diego 31
Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With Tß4 For Chronic Pressure Ulcers 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Skin Ulcers, H2 2012 7
Products under Development for Skin Ulcers – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Galderma S.A., H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Skin Ulcers Therapeutics – Discontinued Products 26
Skin Ulcers Therapeutics – Dormant Products 27

List of Figures
Number of Products under Development for Skin Ulcers, H2 2012 7
Products under Development for Skin Ulcers – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20